Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share ... PRA023 had the potential to be a “pipeline in a product”. Meanwhile, following after PRA023 is PRA052 ...

Merck, of Rahway, N.J., had sold some ophthalmology drugs, but it abandoned the market about a decade ago, divesting itself of the remaining products ... Prometheus Biosciences last year and ...